ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
SERSµDrop: A Platform to Study Cell-Cell Communication via SERS Imaging.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Surface-Enhanced Raman Spectroscopy in Breast Cancer Detection: A Bibliometric Review and Landscape of Global Trends.Biosensors · 2026Review
- AS1411 aptamer-functionalized, cell membrane-camouflaged nanoparticles for targeted tumor cells imaging in the Raman silent region.Analytical and bioanalytical chemistry · 2026Article
- Review
- Gold nanoparticles in skin drug delivery: a bibliometric analysis of research trends from 2015 to 2025.Frontiers in medical technology · 2026Review
- A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.Frontiers in immunology · 2026Article
- SERSµDrop: A Platform to Study Cell-Cell Communication via SERS Imaging.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cell-cell communication is a fundamental aspect of cellular physiology, with implications in early cancer detection, tumor progression, metastasis, and therapeutic resistance. One key mechanism driving intercellular communication involves extracellular vesicles (EVs), which facilitate the transfer of proteins, lipids, and nucleic acids between cells and play a critical role in modulating tumor behavior. Current tools to study EV-mediated communication lack the required spatial and temporal resolution to track EV exchange at single-cell level in physiologically relevant environments. This work introduces SERSµDrop, a microfluidic droplet-based platform integrating surface-enhanced Raman spectroscopy (SERS) for high-resolution monitoring of intercellular communication. In this work we co-encapsulate MCF-7 breast cancer cells and human dermal fibroblasts (HDF) in microdroplets and label them with gold nanostars (AuNSt) functionalized with distinct Raman reporters and surface coatings: poly-L-arginine hydrochloride (AuNSt@PA) for HDFs, and anti-CD81 antibodies (AuNSt@AB) to track small EV release from MCF-7 cells. SERS mapping reveals directional transfer of AuNSt@AB-tagged EVs from MCF-7 to HDFs over 4 days, while AuNSt@PA remains intracellular, confirming their limited exocytic behavior. The platform ensures high cell viability, preserves microdroplet integrity, supports high-throughput screening, and enables multiplexed detection, while minimizing SERS signal dilution through spatial confinement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.